AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01612013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
Study NCT01612013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC plus saline
Description: Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
Study NCT01612013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC plus sodium bicarbonate plus saline
Description: Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
Study NCT01184872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.~Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days.
Study NCT01184872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin or Semi-Synthetic Penicillins (SSPs)
Description: Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.~Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days.
Study NCT00774085 — intervention group
Intervention type: OTHER
Intervention: No intervention was given
Description: Participants included patients treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
Study NCT02518789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol，remifentanil，cis atracurium
Description: Anesthesia maintenance：Intravenous infusion of propofol 4 \~ 6 mg/kg/h, remifentanil 0.1 \~ 0.3 μg/kg/min, intermittent intravenous injection of cis atracurium 0.05 \~ 0.1mg/kg
Study NCT02518789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol，remifentanil，cis atracurium
Description: Anesthesia maintenance：Intravenous infusion of propofol 4 \~ 6 mg/kg/h, remifentanil 0.1 \~ 0.3 μg/kg/min, intermittent intravenous injection of cis atracurium 0.05 \~ 0.1mg/kg
Study NCT04201782 — intervention group
Intervention type: DRUG
Intervention: There are no disallowed treatments
Description: Genetic: SB-728-T or SB-728mR-T No study drug is administered in this study. Subjects who received SB-728-T or SB-728mR-T in a previous trial will be evaluated in this trial for long-term safety and efficacy.
Study NCT00129636 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Additional specific letter written to patient
Study NCT03934775 — intervention group
Intervention type: DEVICE
Intervention: Finapres Nova
Description: Non-invasive mesurement of hemodynamic parameters and heart rate variability
Study NCT00453791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW805858
Description: GW805858 MDI will be given with dose of 150 micrograms per metered actuation and 120 actuations per inhaler. GW805858 MDI comprises a solution of GW805858 in a liquefied hydrofluoroalkane propellant (1,1,1,2-tetrafluoroethane) which is contained in an aluminium alloy can, internally coated with a specified fluoropolymer, fitted with a metering valve.
Study NCT02111083 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: LY275585 administered SC.
Study NCT02111083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: LY275585 administered SC.
Study NCT03634423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweet Spot: Flexible high incentive condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
Study NCT03634423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweet Spot: Flexible low incentive condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
Study NCT02505659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative re-education
Description: Preoperative re-education (behavior): 8 re-education sessions of 30 to 40 minutes, 2 times a week, for 4 weeks
Study NCT04011657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compulsory CDSS
Description: Compulsory CDSS use with prospective review feedback in patients prescribed with piperacillin tazobactam or carbapenems
Study NCT00613496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irbesartan
Description: Irbesartan-tablet (150 mg) 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8 if no contraindication for up titration (investigator will decide on the basis of creatinin, urea and potassium after taking a blood sample) for 9 weeks.
Study NCT00613496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo-tablet, 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8.
Study NCT02385747 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hystroscopy
Description: Detailed hysteroscopic examination under general anesthesia Once the cavity entered, a panoramic view of the uterine cavity then systematic; first the fundus, then anterior, posterior and lateral walls of the uterus consecutively, ending by visualization of the uterine -tubal junctions, The thickness, colour, aspect and vasculature of the mucous membrane lining the uterine cavity was observed and recorded. If there is any intrauterine pathology detected; the shape, size and site were estimated.
Study NCT00453791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo MDI will be given to the subjects.
Study NCT03512171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Description: One oral dose of dextroamphetamine (0.43mg/kg). The amphetamine is given in order to induce the release of their own dopamine for study with positron emission tomography (PET).
Study NCT03512171 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One oral dose of placebo to estimate D2 receptor levels at baseline with PET imaging (necessary to calculate dopamine release in the amphetamine condition).
Study NCT03512171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]Fallypride
Description: Radioligand for measuring dopamine D2 receptors with positron emission tomography (PET)
Study NCT03512171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: [18F]Fallypride
Description: Radioligand for measuring dopamine D2 receptors with positron emission tomography (PET)
Study NCT03512171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]-FE-PE2I
Description: Radioligand for measuring dopamine transporters with positron emission tomography (PET)
Study NCT01681160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: procedure:maggot therapy
Description: each times in maggot therapy continued for three days.wound assessment was done before and after any intervention
Study NCT01681160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: patients receive ordinary treatment for diabetic foot
Study NCT03634423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweet Spot: Rigid high incentive condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
Study NCT03634423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweet Spot: Rigid low incentive condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
Study NCT03634423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOTW: High incentive control condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
Study NCT03634423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOTW: Low incentive control condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
Study NCT03851718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture Procedure
Description: Each session will run about 30\~40 minutes at the Family Medicine Clinic and performed by a licensed acupuncturist. The expense of all three sessions will be reimbursed by the project, not billed to the participant. The following points CV17, ST18 (bilateral), ST36 (bilateral), SI1(bilateral) and LR3(bilateral) , adopted from TCM classic text and previous studies done in China, will be used for all three sessions .
Study NCT03634423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOTW: High incentive treatment condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
Study NCT03634423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOTW: Low incentive treatment condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
Study NCT03851718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Power pumping
Description: It suggests the mom to set at least one hour and two hours preferably for the power pumping at least three days within a 5 weekday period, preferably on 3 consecutive days. During this one hour, the moms will be advised to pump for 20 minutes, rest for 10 minutes, pump for 10 minutes, then rest for 10 minutes and pump for 10 minutes. Alternatively they can also opt to pump and rest for every 10 minutes during the hour.
Study NCT00453193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: 4 mg/m\^2 IV weekly for 4 weeks then every 2 weeks
Study NCT00453193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 30 mg IV three times weekly
Study NCT03634423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Think Twice: Control condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
Study NCT03634423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Think Twice: Treatment condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
Study NCT00572039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PST
Description: PST will be delivered in subjects' homes over the course of 6 weeks.
Study NCT00572039 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ST
Description: ST will be delivered in subjects' homes over the course of 6 weeks.
Study NCT02894567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative test during a deep brain stimulation surgery
Description: The spiderSTN lead is inserted in a selected track in the brain, and is connected to external neuro-recorder/stimulator . Once the intraoperative test phase is completed, the test devices are removed and the DBS surgery resumes.
Study NCT01170390 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: All participants (Aviane)
Description: 20 mcg EE/0.1 mg LNG cyclically
Study NCT03634423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WDR: Control condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
Study NCT01170390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Portia
Description: 30 mcg EE/0.15 mg LNG cyclically
Study NCT03634423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WDR: Treatment condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
Study NCT00433836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg.
Study NCT00433836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg.
Study NCT00440843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine (Zyprexa)
Description: OLZ
Study NCT00440843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Typicals
Description: Stay on typicals regimen
Study NCT00879216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483
Description: 4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
Study NCT00879216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
Study NCT01170390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aviane
Description: 20 mcg EE/0.1 mg LNG continuously dosed
Study NCT01922453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music and Sound
Study NCT02158351 — intervention group
Intervention type: PROCEDURE
Intervention: liver and white adipose tissue biopsies
Study NCT02171624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Study NCT02171624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quinidine
Study NCT03518684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalis
Description: A specially-designed sterile obstetric gel (Natalis) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that has a purely physical activity. It contains propylene glycol, glycerol, sodium chloride, xanthan gum, hydroxyethylcellulose and water.~Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child using the sterile obstetric gel applicator without any manipulation or massaging. Additional obstetric gel will be added 15-30 minutes after rupture of the membranesOnce the head of the child is visible, the mouth and nose region will be wiped clean. A dry towel will be used to liberate the child in order to prevent the child from slipping
Study NCT00656526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine, perineural injection, intraoperatively
Description: 0.5 cc lidocaine, one single injection over the dorsal root.
Study NCT02842450 — intervention group
Intervention type: DEVICE
Intervention: Photos + definitions
Description: A broad group of experts (19 proctology and a dermatologist) will be contacted to choose two typical images of LAP (superficial ulceration, deep ulceration ...). 12 photos lesion initially selected by experts.
Study NCT02842450 — intervention group
Intervention type: OTHER
Intervention: definitions only
Study NCT03196895 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight reduction training
Description: 6 one-hour sessions of conventional weight reduction training
Study NCT03196895 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PPG training
Description: Four 90-minute sessions of glycemic load and exercise training
Study NCT03196895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPG training
Description: Four 90-minute sessions of glycemic load and exercise training
Study NCT03196895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: discrete BG feedback
Description: Blood glucose feedback from structured self-monitoring of blood glucose
Study NCT03196895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: continuous BG feedback
Description: blood glucose feedback from continuous glucose monitoring
Study NCT01580254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IOPIZE© Latanoprost eyedrops
Description: patients will receive in each eligible eye one drop of IOPIZE© Latanoprost eyedrops once a day, in the evening (8pm), for two months
Study NCT01580254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GALAXIA© Latanoprost eyedrops
Description: patients will receive in each eligible eye one drop of GALAXIA© Latanoprost eyedrops once a day, in the evening (8pm), for two months
Study NCT01580254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost RATIOPHARM© latanoprost eyedrops
Description: patients will receive in each eligible eye one drop of Latanoprost RATIOPHARM© Latanoprost eyedrops once a day, in the evening (8pm), for two months
Study NCT02746198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: probiotic dairy drink
Study NCT02746198 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: acidified milk
Study NCT04107298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUNDANCE™ Drug Coated Balloon
Description: Angioplasty procedure with a sirolimus-coated, percutaneous transluminal angioplasty (PTA) balloon catheter
Study NCT04693195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-5937
Description: Oral administration of BLU-5937 tablets
Study NCT04693195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of matching placebo for BLU-5937 tablets
Study NCT02352168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide nasal spray
Description: 64mcg/1putt, 1 putt/nostril,b.i.d
Study NCT02352168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 putt/nostril,b.i.d
Study NCT03972150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: Solution for infusion
Study NCT03972150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Solution for infusion
Study NCT00656526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: 0.5 cc %2 lidocaine,single injection
Study NCT03666572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium infantis
Description: Bifidobacterium longum subsp. infantis (EVC001)
Study NCT03750721 — intervention group
Intervention type: OTHER
Intervention: Role of rifampin in staphylococcal PJI
Description: the aim is to determine if the dose and the duration of rifampin influenced the prognosis
Study NCT05348434 — intervention group
Intervention type: PROCEDURE
Intervention: 3D printed polyether ether ketone facial implants in repairing maxillofacial deformities
Description: All patients underwent Computed Tomography (CT) scans under the condition of providing a large number of slices (more than 200 slices) per axis, and the thickness of each slice is less than 1 mm with 64-bit resolution, Then the design of the required facial implant was carried out in coordination between the designer and the surgical team. The final form of the facial implant was printed from PolyEther Ether Ketone (PEEK), and then surgical work was performed for patients under general anaesthetic according to the appropriate surgical entrance. The implants were fixed in place using titanium screws
Study NCT03937778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deep pressure block
Description: Apply deep pressure block by using blood pressure cuff.
Study NCT00359996 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: health disparities collaborative
Description: The HDC incorporates rapid quality improvement (QI), a chronic care model, and best practices. This study determines if the HDC improves diabetes care and whether more intensive interventions with additional learning sessions for health centers, provider training in behavioral change, and patient empowerment materials enhance care further.
Study NCT00359996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No additional educational sessions
Study NCT03666572 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bifidobacterium infantis
Description: Bifidobacterium longum subsp. infantis (EVC001)
Study NCT03666572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium infantis with prebiotic Lacto-N-neotetraose [LNnT]
Description: Bifidobacterium infantis with prebiotic Lacto-N-neotetraose \[LNnT\]
Study NCT03929107 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells
Description: patient's T cells were seperated and engineered into Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells, and retransfused into the patient for treatment of their B cell lymphoma.